CA2900982C - Ultrapure tetrahydrocannabinol-11-oic acids - Google Patents

Ultrapure tetrahydrocannabinol-11-oic acids Download PDF

Info

Publication number
CA2900982C
CA2900982C CA2900982A CA2900982A CA2900982C CA 2900982 C CA2900982 C CA 2900982C CA 2900982 A CA2900982 A CA 2900982A CA 2900982 A CA2900982 A CA 2900982A CA 2900982 C CA2900982 C CA 2900982C
Authority
CA
Canada
Prior art keywords
scleroderma
pulmonary fibrosis
ultrapure
fibrosis
oic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2900982A
Other languages
English (en)
French (fr)
Other versions
CA2900982A1 (en
Inventor
Mark Tepper
Dean A. Frey
David Goeddel
Karl E. Reineke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of CA2900982A1 publication Critical patent/CA2900982A1/en
Application granted granted Critical
Publication of CA2900982C publication Critical patent/CA2900982C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2900982A 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids Active CA2900982C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Publications (2)

Publication Number Publication Date
CA2900982A1 CA2900982A1 (en) 2014-08-21
CA2900982C true CA2900982C (en) 2021-06-01

Family

ID=51354671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900982A Active CA2900982C (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP3851101A1 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN110946854A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
AU2017258765A1 (en) * 2016-04-29 2018-11-29 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
RU2019103297A (ru) * 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
AR123027A1 (es) * 2020-07-21 2022-10-26 Np Pharma Holdings Llc Composiciones y métodos de cannabinoides para el tratamiento del dolor y la inflamación de las articulaciones

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1409473A2 (en) * 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
AU2003297074A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
KR20080000660A (ko) 2005-04-21 2008-01-02 오르펀 메디칼, 인크. 초순수 4-메틸피라졸의 제조 방법
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
WO2009158499A2 (en) 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
WO2014127016A2 (en) 2014-08-21
US9820964B2 (en) 2017-11-21
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
EP2956133A2 (en) 2015-12-23
US20170071899A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18
AU2018258159B2 (en) 2020-01-02
JP2021185166A (ja) 2021-12-09
US9801849B2 (en) 2017-10-31
US20190091200A1 (en) 2019-03-28
KR20190139327A (ko) 2019-12-17
CN105228613A (zh) 2016-01-06
JP2016510340A (ja) 2016-04-07
BR112015019180A8 (pt) 2018-01-30
EP3851101A1 (en) 2021-07-21
US20170071898A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
CN110946854A (zh) 2020-04-03
US20200093784A1 (en) 2020-03-26
US20220117931A1 (en) 2022-04-21
US11052066B2 (en) 2021-07-06
EP2956133A4 (en) 2016-12-21
AU2018258159A1 (en) 2018-11-22
US20170071900A1 (en) 2017-03-16
KR20160002709A (ko) 2016-01-08
JP6689078B2 (ja) 2020-04-28
AU2014216440B2 (en) 2018-08-09
US20180177757A1 (en) 2018-06-28
US20150141501A1 (en) 2015-05-21
US10154986B2 (en) 2018-12-18
AU2014216440A1 (en) 2015-08-20
JP2019031505A (ja) 2019-02-28
US10369131B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
AU2018258159A1 (en) Ultrapure tetrahydrocannabinol-11-oic acids
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
PH12013500215B1 (en) Corticosteroids for the treatment of joint pain
HK1232147A1 (zh) 用於治疗纤维化的赛尼克韦罗
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
WO2017087608A8 (en) Modulators of ror-gamma
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER DISPLAYS
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
HK1214765A1 (zh) 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
EP2651407A4 (en) 3-METHANSULFONYLPROPIONITRILE FOR THE TREATMENT OF INFLAMMATION AND PAIN
WO2011025286A3 (ko) 리포테이코익산 유래 당지질 및 이를 포함하는 조성물
CA2869599C (en) Compounds which inhibit neuronal exocytosis (ii)
EP3661600A4 (en) FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
HK1202448A1 (en) Topical formulation for administering a compound
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
RU2016106829A (ru) Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
WO2015019304A3 (fr) Compositions à libération continue à base d'acide hyaluronique, et leurs applications thérapeutiques
MA49794A (fr) Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire
EA201690659A1 (ru) Композиции аморфного магнийзамещенного фосфата кальция и их применение
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190212

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240814